Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Acquired by Mn Services Vermogensbeheer B.V.

Mn Services Vermogensbeheer B.V. boosted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 81,500 shares of the medical equipment provider’s stock after purchasing an additional 1,300 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Zimmer Biomet were worth $8,609,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Equity Investment Corp boosted its stake in Zimmer Biomet by 57.2% during the fourth quarter. Equity Investment Corp now owns 1,021,062 shares of the medical equipment provider’s stock valued at $107,855,000 after buying an additional 371,653 shares in the last quarter. Illinois Municipal Retirement Fund lifted its holdings in Zimmer Biomet by 29.1% in the 4th quarter. Illinois Municipal Retirement Fund now owns 93,460 shares of the medical equipment provider’s stock valued at $9,872,000 after acquiring an additional 21,046 shares during the last quarter. Brown Financial Advisors grew its stake in shares of Zimmer Biomet by 3.4% in the 4th quarter. Brown Financial Advisors now owns 9,887 shares of the medical equipment provider’s stock worth $1,044,000 after purchasing an additional 321 shares during the last quarter. Skylands Capital LLC raised its holdings in shares of Zimmer Biomet by 87.5% in the 4th quarter. Skylands Capital LLC now owns 6,986 shares of the medical equipment provider’s stock worth $738,000 after purchasing an additional 3,261 shares in the last quarter. Finally, New World Advisors LLC lifted its stake in Zimmer Biomet by 7.3% during the fourth quarter. New World Advisors LLC now owns 3,813 shares of the medical equipment provider’s stock valued at $403,000 after purchasing an additional 260 shares during the last quarter. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Stock Up 0.3 %

ZBH opened at $104.32 on Friday. The company has a market capitalization of $20.77 billion, a PE ratio of 23.44, a price-to-earnings-growth ratio of 1.95 and a beta of 1.02. The business has a 50-day moving average of $105.72 and a 200-day moving average of $107.38. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $97.69 and a fifty-two week high of $133.90. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the previous year, the firm earned $2.20 earnings per share. Equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date is Monday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Analyst Ratings Changes

Several research analysts have issued reports on ZBH shares. Barclays decreased their price target on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research report on Monday, February 10th. Royal Bank of Canada reduced their price objective on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Finally, Stifel Nicolaus raised their price objective on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.